Why COMPASS Pathways plc’s (CMPS) Stock Is Up 5.40%
As of Tuesday, October 20, COMPASS Pathways plc’s CMPS share price has surged by 5.40%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Commentary & Analysis
Why COMPASS Pathways plc’s (CMPS) Stock Is Up 10.77%
As of Thursday, September 17, COMPASS Pathways plc’s CMPS share price has surged by 10.77%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why COMPASS Pathways plc’s (CMPS) Stock Is Down 5.16%
As of Tuesday, September 15, COMPASS Pathways plc’s CMPS share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why COMPASS Pathways plc’s (CMPS) Stock Is Down 5.27%
As of Thursday, September 10, COMPASS Pathways plc’s CMPS share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why COMPASS Pathways plc’s (CMPS) Stock Is Up 6.41%
As of Wednesday, September 09, COMPASS Pathways plc’s CMPS share price has surged by 6.41%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CMPS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,610.5 | $229.3 | 52% |
|
| Shares Out (Mil) | 135.0 | 53.4 | 68% |
|
| Institutional Ownership | 96.8% | 92.9% | 71% |
|
| Float (Mil) | 107.0 | 41.4 | 62% |
|
| Beta | 2.53 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 2,623 | 533 | 85% |
|
| Price Change (52-week) |
78.9% | 47.5% | 92% |
|
| Growth | CMPS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (36.7%) | (10.1%) | 11% |
|
| EPS (5yr) | 2.8% | 15.8% | 35 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.7%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.330) | ($1.505) | ($1.433) | |
| Month Ago EPS | ($0.330) | ($1.505) | ($1.433) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.313) | ($0.995) | ($1.085) | |
| Year/Year Chg | (82.4%) | (51.1%) | (70.8%) | |
| Financials | CMPS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($394) | ($44) | 4% |
|
| EPS (TTM) | ($3.610) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($161) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $53 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $1,462 | $179 | 45% |
|
| Valuation | CMPS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 18.76 | 2.17 | 95% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CMPS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (98.8%) | (47.1%) | 6% |
|
| ROE | (319.1%) | (53.5%) | 3% |
|
| Liabilities to Assets | 83.2% | 29.3% | 77% |
|
| F-Score | 1 | 2 | 1% |
|
COMPASS Pathways plc did not pass any screens on 10/22/2026.
